MedTrace Logo

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

NCT03296800 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-07-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin. The study is to evaluate how safe the study drug is and how well the study drug is tolerated when taken with probenecid, verapamil or rifampin.

Conditions

Interventions

DRUG

Bexagliflozin

Bexagliflozin 20 mg, tablet; qd

DRUG

Probenecid

Probenecid tablets, 500 mg; bid

DRUG

Rifampin

Rifampin, 600 mg (2 x 300 mg capsules); qd

DRUG

Verapamil

Verapamil hydrochloride tablet, 120 mg; qd

Sponsors & Collaborators

  • Theracos

    lead INDUSTRY

Principal Investigators

  • Mason Freeman, M.D. · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-27
Primary Completion
2017-12-06
Completion
2017-12-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296800 on ClinicalTrials.gov